A Novel Genomic Framework for Personalized Medicine: Optimizing LMTX for Tau Proteins in Alzheimer's
ISEF · 2025 Computational Biology and Bioinformatics
Overview
Tau protein aggregation is a hallmark of Alzheimer's disease (AD), disrupting neuronal function and impairing synaptic signaling. The clinical efficacy of tau aggregation inhibitors like TRx0237 (LMTX) has been inconsistent, mainly due to patient-specific genetic variations in tau protein that alter its structure, binding affinity, and drug metabolism. This project employs novel custom-built Large Language Model Systems (LLMs) each equipped with Drug-Target Interaction (DTI) prediction tools to rapidly design, test, and optimize new LMTX derivatives with enhanced binding affinity for genetically diverse tau proteins. In silico validation was conducted using molecular docking simulations, deep learning-based binding site predictions, and molecular dynamics modeling to assess drug stability, interaction strength, and potential off-target effects. These simulations confirmed that the newly designed LMTX analogs exhibit significantly increased tau-binding stability, reduced aggregation propensity, and improved microtubule stabilization. Furthermore, predictive cognitive modeling, based on established correlations between tau pathology and cognitive decline, projects measurable improvements in MMSE scores, suggesting enhanced therapeutic efficacy. The significance of this in silico validation lies in its ability to rapidly and systematically evaluate drug candidates before costly in vitro or clinical trials, accelerating the discovery of effective, patient-specific therapeutics. These findings have broad implications for precision medicine, offering a scalable computational framework for designing genetically tailored neuroprotective treatments that could improve drug efficacy, minimize side effects, and support early intervention strategies in AD.
Competition history
- ISEF 2025
Resources
Related projects
ISEF · 2024
Identification of Novel Target Genes and ML-Based Drug Repurposing and Discovery for Alzheimer’s Disease in the Presence of Metabolic Comorbidities
ISEF · 2021
Tackling Tau: Identifying a Novel Inhibitor for the MSUT-2 Protein based on Quantum Machine Learning for the Identification of Treatments of Neurodegenerative Diseases
ISEF · 2024
Novel Drug Discovery Methodology Using Machine Learning for Gene Expression-Based Virtual Screening Predicts Novel Compounds To Reverse Alzheimer's Disease With Applications to Cancer and Longevity by Inhibiting CtBP2 Expression
ISEF · 2022
In silico High-Throughput Identification of Novel Dual Amyloid Beta and Tau Aggregation Inhibitors for Alzheimer's Disease Treatments
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair